Evaluation of heparin cofactor II-thrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB mice

Molecular Genetics and Metabolism

Volumn 99, Issue 3, 2010, Pages 269-274

  Langford Smith, Kia ^a   Arasaradnam, Malani ^a   Wraith, J Ed ^b   Wynn, Rob ^c   Bigger, Brian W ^a,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Biomarker; Blood spots; Dermatan sulphate; Heparan sulphate; Heparin cofactor II thrombin; Hurler syndrome; Mucopolysaccharide disease; Newborn screening; Sanfilippo syndrome; Serpin protease complex; Serum

Indexed keywords

BIOLOGICAL MARKER; DERMATAN SULFATE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN COFACTOR II; THROMBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HURLER SYNDROME; IN VIVO STUDY; MOUSE; NEWBORN SCREENING; NONHUMAN; PRIORITY JOURNAL; RELIABILITY; SANFILIPPO SYNDROME; TREATMENT OUTCOME;

ANIMALS; BIOLOGICAL MARKERS; BLOOD SPECIMEN COLLECTION; DERMATAN SULFATE; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPARIN COFACTOR II; HEPARITIN SULFATE; HUMANS; MICE; MICE, INBRED C57BL; MUCOPOLYSACCHARIDOSIS I; MUCOPOLYSACCHARIDOSIS III; THROMBIN;

MURINAE; MUS;

EID: 76349090897     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2009.10.175     Document Type: Article

References (18)

1. Neufeld E.F., and Muenzer J. The Metabolic and Molecular Bases of Inherited Disease (2001), The McGraw-Hill Companies
2. Wraith J.E., Clarke L.A., Beck M., Kolodny E.H., Pastores G.M., Muenzer J., Rapoport D.M., Berger K.I., Swiedler S.J., Kakkis E.D., Braakman T., Chadbourne E., Walton-Bowen K., and Cox G.F. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-l-iduronidase (laronidase). J. Pediatr. 144 (2004) 581-588
3. Wraith J.E. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II. Acta Paediatr. Suppl. 97 (2008) 76-78
4. Harmatz P., Giugliani R., Schwartz I.V., Guffon N., Teles E.L., Miranda M.C., Wraith J.E., Beck M., Arash L., Scarpa M., Ketteridge D., Hopwood J.J., Plecko B., Steiner R., Whitley C.B., Kaplan P., Yu Z.F., Swiedler S.J., and Decker C. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol. Genet. Metab. 94 (2008) 469-475
5. Peters C., and Steward C.G. Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone Marrow Transplant. 31 (2003) 229-239
6. Peters C., Shapiro E.G., Anderson J., Henslee-Downey P.J., Klemperer M.R., Cowan M.J., Saunders E.F., deAlarcon P.A., Twist C., Nachman J.B., Hale G.A., Harris R.E., Rozans M.K., Kurtzberg J., Grayson G.H., Williams T.E., Lenarsky C., Wagner J.E., and Krivit W. Hurler syndrome. II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group. Blood 91 (1998) 2601-2608
7. Krivit W., Pierpont M.E., Ayaz K., Tsai M., Ramsay N.K., Kersey J.H., Weisdorf S., Sibley R., Snover D., McGovern M.M., et al. Bone-marrow transplantation in the Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Biochemical and clinical status 24 months after transplantation. N. Engl. J. Med. 311 (1984) 1606-1611
8. Yamada Y., Kato K., Sukegawa K., Tomatsu S., Fukuda S., Emura S., Kojima S., Matsuyama T., Sly W.S., Kondo N., and Orii T. Treatment of MPS VII (Sly disease) by allogeneic BMT in a female with homozygous A619V mutation. Bone Marrow Transplant. 21 (1998) 629-634
9. Church H., Tylee K., Cooper A., Thornley M., Mercer J., Wraith E., Carr T., O'Meara A., and Wynn R.F. Biochemical monitoring after haemopoietic stem cell transplant for Hurler syndrome (MPSIH): implications for functional outcome after transplant in metabolic disease. Bone Marrow Transplant. 39 (2007) 207-210
10. Wynn R.F., Wraith J.E., Mercer J., O'Meara A., Tylee K., Thornley M., Church H.J., and Bigger B.W. Improved metabolic correction in patients with lysosomal storage disease treated with hematopoietic stem cell transplant compared with enzyme replacement therapy. J. Pediatr. 154 (2009) 609-611
11. Fuller M., Rozaklis T., Ramsay S.L., Hopwood J.J., and Meikle P.J. Disease-specific markers for the mucopolysaccharidoses. Pediatr. Res. 56 (2004) 733-738
12. Randall D.R., Sinclair G.B., Colobong K.E., Hetty E., and Clarke L.A. Heparin cofactor II-thrombin complex in MPS I: a biomarker of MPS disease. Mol. Genet. Metab. 88 (2006) 235-243
13. Randall D.R., Colobong K.E., Hemmelgarn H., Sinclair G.B., Hetty E., Thomas A., Bodamer O.A., Volkmar B., Fernhoff P.M., Casey R., Chan A.K., Mitchell G., Stockler S., Melancon S., Rupar T., and Clarke L.A. Heparin cofactor II-thrombin complex: a biomarker of MPS disease. Mol. Genet. Metab. 94 (2008) 456-461
14. Clarke L.A., Russell C.S., Pownall S., Warrington C.L., Borowski A., Dimmick J.E., Toone J., and Jirik F.R. Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-l-iduronidase gene. Hum. Mol. Genet. 6 (1997) 503-511
15. Bhaumik M., Muller V.J., Rozaklis T., Johnson L., Dobrenis K., Bhattacharyya R., Wurzelmann S., Finamore P., Hopwood J.J., Walkley S.U., and Stanley P. A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome). Glycobiology 9 (1999) 1389-1396
16. Li H.H., Yu W.H., Rozengurt N., Zhao H.Z., Lyons K.M., Anagnostaras S., Fanselow M.S., Suzuki K., Vanier M.T., and Neufeld E.F. Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding alpha-N-acetylglucosaminidase. Proc. Natl. Acad. Sci. USA 96 (1999) 14505-14510
17. Tomatsu S., Gutierrez M.A., Ishimaru T., Pena O.M., Montano A.M., Maeda H., Velez-Castrillon S., Nishioka T., Fachel A.A., Cooper A., Thornley M., Wraith E., Barrera L.A., Laybauer L.S., Giugliani R., Schwartz I.V., Frenking G.S., Beck M., Kircher S.G., Paschke E., Yamaguchi S., Ullrich K., Isogai K., Suzuki Y., Orii T., and Noguchi A. Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses. J. Inherit. Metab. Dis. 28 (2005) 743-757
18. Ofosu F.A., Modi G.J., Smith L.M., Cerskus A.L., Hirsh J., and Blajchman M.A. Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways. Blood 64 (1984) 742-747